Advertisement


John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

2024 ASH Annual Meeting

Advertisement

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combination of imetelstat and ruxolitinib in patients with intermediate- or high-risk myelofibrosis (Abstract 998).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The IMproveMF study is a study of imetelstat, the telomerase inhibitor, the first in class telomerase inhibitor, which is an infusional agent in patients with myelofibrosis that are on a stable dose of ruxolitinib with the add-on metals stat to try to improve upon response, spleen, symptom, and biomarkers of response. So this is a phase one B study dose escalation starting at 4.7 milligrams per kilogram IV every four weeks added onto the stable dose of ruxolitinib. The patients had to been on for at least 12 weeks and a stable dose for four weeks. And what we saw in this phase one B study all the way up to 9.4 milligrams per kilogram was no dose limiting toxicity. So we didn't see significant myelosuppression, GI toxicity, or any other non hematologic toxicity. Any hematologic toxicity we saw was both transient and recoverable, allowing us to continue dosing imetelstat. So it really did prove that imetelstat which is approved, I should say in lower risk transfusion dependent MDS patients with an anemia goal in myelofibrosis can be delivered as an add-on strategy to ruxolitinib safely. We're now beginning to look at the readout of efficacy. We gave some preliminary results showing that at the higher doses of imetelstat 9.4 milligram per kilogram, which is the dose I should point out, that's being evaluated in the phase three randomized. Phase three is a single agent in the relapse refractory setting is a well tolerated dose and has shown already some preliminary activity in terms of reduction in spleen and symptom burden above and beyond what we were seeing with the single agent ruxolitinib initially. So we need to expand this cohort, continue to follow the patients for outcome measures like progression-free survival, maybe even overall survival, and make sure these responses are durable, and that's the next step. We'll also add a cohort of patients that will likely be treatment naive patients, so adding imetelstat plus ruxolitinib upfront rather than this delayed add-on strategy. So more to come with imetelstat. And of course we're still waiting for the randomized phase three single agent in the relapse refractory setting to read out. Hopefully by 2026.

Related Videos

Leukemia

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. The new findings may indicate promising avenues for further research on treatment resistance and disease relapse (Abstract 633).

Leukemia

Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed the addition of blinatumomab to chemotherapy in newly diagnosed childhood standard-risk B-cell acute lymphoblastic leukemia (ALL). She explains how the combination may be considered a major breakthrough and new treatment standard in this patient population (Abstract 1).

Leukemia

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-duration acalabrutinib/venetoclax—with or without obinutuzumab—with investigator’s choice of chemoimmunotherapy in fit patients with treatment-naïve chronic lymphocytic leukemia (CLL). According to Dr. Brown, this trial met its primary endpoint, with improved progression-free survival reported with this first all-oral fixed-duration regimen.

Hematologic Malignancies

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). The researchers evaluated a preclinical mouse model of GVHD with defined diet fiber concentrations and analyzed the dietary patterns of 173 allo-HCT patients (Abstract 259).

Leukemia

Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovalent Bruton’s tyrosine kinase inhibitor pirtobrutinib with the BCL2 inhibitor venetoclax and the CD20 monoclonal antibody obinutuzumab in previously untreated chronic lymphocytic leukemia (CLL). Dr. Jain reviews the findings at both 6 and 12 months of combined therapy. 

Advertisement

Advertisement




Advertisement